NASDAQ · DTIL
Healthcare · Biotechnology
$6.61
Up+$0.04 (+0.61%)
Updated Sep 16, 2026, 1:51 PM
SID Score
5.7/10
Composite research score
Smart Money
—
Institutional and insider signal
Price performance
1M range · 20 trading sessions · Daily adjusted prices
DTIL closed at $6.61 after 20 trading sessions, down 19.68% for the selected period.
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Sep 15, 2026 | $6.86 | $6.90 | $6.48 | $6.61 | 314.61K |
| Sep 14, 2026 | $7.13 | $7.255 | $6.85 | $6.86 | 236.35K |
| Sep 11, 2026 | $7.28 | $7.38 | $7.06 | $7.17 | 191.4K |
| Sep 10, 2026 | $7.16 | $7.27 | $7.035 | $7.24 | 143.43K |
| Sep 9, 2026 | $7.38 | $7.49 | $7.15 | $7.25 | 273.5K |
| Sep 8, 2026 | $7.41 | $7.49 | $7.20 | $7.40 | 139.96K |
| Sep 4, 2026 | $7.32 | $7.575 | $7.32 | $7.47 | 124.28K |
| Sep 3, 2026 | $7.48 | $7.55 | $7.23 | $7.37 | 186.99K |
| Sep 2, 2026 | $7.66 | $7.82 | $7.24 | $7.45 | 358.92K |
| Sep 1, 2026 | $7.54 | $7.68 | $7.49 | $7.64 | 170.93K |
| Aug 31, 2026 | $7.75 | $7.80 | $7.4925 | $7.64 | 214.81K |
| Aug 28, 2026 | $8.37 | $8.43 | $7.72 | $7.78 | 222.53K |
| Aug 27, 2026 | $8.54 | $8.54 | $8.21 | $8.40 | 275.05K |
| Aug 26, 2026 | $8.58 | $8.66 | $8.33 | $8.49 | 263.21K |
| Aug 25, 2026 | $8.43 | $8.75 | $8.33 | $8.55 | 418.19K |
| Aug 24, 2026 | $8.82 | $8.82 | $8.36 | $8.45 | 232.78K |
| Aug 21, 2026 | $8.81 | $9.08 | $8.63 | $8.85 | 305.18K |
| Aug 20, 2026 | $8.60 | $9.3399 | $8.59 | $8.72 | 496.26K |
| Aug 19, 2026 | $8.34 | $8.98 | $8.30 | $8.50 | 428.44K |
| Aug 18, 2026 | $7.44 | $8.25 | $7.44 | $8.23 | 301.63K |
The latest Smart Investors Daily articles mentioning DTIL.
DTIL research
Company profile and research snapshot.
Precision BioSciences Inc is a genome editing company dedicated to improving life through its genome editing platform, ARCUS. It leverages ARCUS in the development of its product candidates, which are designed to treat human diseases and provide food and agricultural solutions. The ARCUS is in its relatively small size which potentially allows delivery to a wider range of cells and tissues using viral and non-viral gene delivery methods.
Visit company websiteConsensus and target data currently published for this company.
| Date | Firm | Rating | Target |
|---|---|---|---|
| Aug 3, 2026 | HC Wainwright & Co. | Buy | — |
| Jul 9, 2026 | HC Wainwright & Co. | Buy | — |
| Jun 9, 2026 | Oppenheimer | Outperform | — |
| May 27, 2026 | HC Wainwright & Co. | Buy | — |
| May 21, 2025 | HC Wainwright & Co. | Buy | — |
No generated briefing is available yet.
Benzinga · Aug 27, 2026
iECURE, a private clinical-stage genome editing company, reported preliminary safety observations from all nine participants dosed with ECUR-506 across the low-, intermediate- and high-dose cohorts, saying the therapy
Benzinga · Aug 24, 2026
PBGENE-DMD is Precision's wholly owned in vivo gene editing program designed to durably improve function. This novel approach, aiming to restore near full-length dystrophin, is applicable for up to 60% of DMD
Benzinga · Aug 20, 2026
iECURE has licensed the ARCUS® nuclease from Precision BioSciences for four gene insertion programs including OTC, CTLN1 and PKU.
SeekingAlpha · Aug 18, 2026
Precision BioSciences' direct clinical evidence and pipeline optionality outweigh the early-stage risks. Find out why DTIL stock is a speculative Buy.
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
The latest Smart Investors Daily articles mentioning DTIL.
